Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.57 |
| ▸ | CES1 | P23141 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 4/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.55 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 5/20 | 0.46 |
| ▸ | RAB9A | P51151 | 5/20 | 0.46 |
| ▸ | PKM | P14618 | 4/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.46 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.46 |
| ▸ | MITF | O75030 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30499331 | 1.00 | CES2 (0.57) | CES2CES1LMNAL3MBTL1NAPRT | |
| SCHEMBL3349775 | 0.84 | CES2 (0.57) | CES2CES1LMNAL3MBTL1NAPRT | |
| SCHEMBL4318952 | 0.83 | CES2 (0.75) | CES2CES1LMNAL3MBTL1NAPRT | |
| SCHEMBL6611666 | 0.82 | CES2 (0.59) | CES2CES1LMNAL3MBTL1NAPRT | |
| SCHEMBL755762 | 0.82 | LMNA (0.63) | CES2CES1LMNAL3MBTL1NAPRT | |
| SCHEMBL4336990 | 0.80 | CES2 (0.57) | CES2CES1LMNAL3MBTL1NAPRT | |
| SCHEMBL4341948 | 0.80 | ALDH1A1 (0.48) | CES2CES1LMNAL3MBTL1NAPRT | |
| Hydrochloric Acid SCHEMBL1769091 | 0.80 | LMNA (0.61) | CES2CES1LMNAL3MBTL1NAPRT | |
| SCHEMBL21585663 | 0.79 | CES2 (0.52) | CES2CES1LMNAL3MBTL1NAPRT | |
| SCHEMBL4361791 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4828407-B2 | — | — | 2011-11-30 | — | — | JP | claimed |
| EP-1608377-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING INHIBITORS OF FAB I AND FURTHER ANTIBIOTICS | Affinium Pharmaceuticals, Inc. (CA) | 2005-12-28 | — | — | EP | claimed |
| EP-1594869-A2 | 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF | Targacept, Inc. (US) | 2005-11-16 | — | — | EP | claimed |
| US-20050187264-A1 | Phosphodiesterase iv inhibitor containing pyridylacrylamide derivative | TSUMURA & CO. (JP) | 2005-08-25 | — | — | US | claimed |
| EP-1495757-A1 | PHOSPHODIESTERASE IV INHIBITOR CONTAINING PYRIDYLACRYLAMIDE DERIVATIVE | TSUMURA & CO. (JP) | 2005-01-12 | — | — | EP | claimed |
| WO-2004082586-A2 | PHAMACEUTICAL COMPOSITIONS COMPRISING INHIBITORS OF FAB I AND FURTHER ANTIBIOTICS | AFFINIUM PHARMACEUTICALS, INC. (US) | 2004-09-30 | — | — | WO | claimed |
| WO-2004076449-A2 | 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF | TARGACEPT, INC. (US) | 2004-09-10 | — | — | WO | claimed |
| US-6313153-B1 | ADMINISTERING PYRIDYLACRYLAMIDE COMPOUND FOR THERAPY OF NEPHRITIS | TSUMURA & CO. (JP) | 2001-11-06 | — | — | US | claimed |
| EP-1000935-A1 | PYRIDYLACRYLAMIDE DERIVATIVES AND NEPHRITIS REMEDIES AND TGF-$g(b) INHIBITORS CONTAINING THE SAME | TSUMURA & CO. (JP) | 2000-05-17 | — | — | EP | claimed |
| US-20230312646-A1 | ANTIBACTERIAL PEPTIDES | Universite de Bordeaux (FR) | 2023-10-05 | — | — | US | disclosed |
| CN-116096712-A | Novel compounds | NRG治疗有限公司 | 2023-05-09 | — | — | CN | disclosed |
| EP-4172174-A1 | ANTIBACTERIAL PEPTIDES | Centre National de la Recherche Scientifique (FR) | 2023-05-03 | — | — | EP | disclosed |
| WO-2022002951-A1 | ANTIBACTERIAL PEPTIDES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-01-06 | — | — | WO | disclosed |
| EP-3932935-A1 | ANTIBACTERIAL PEPTIDES | Centre National de la Recherche Scientifique (FR) | 2022-01-05 | — | — | EP | disclosed |
| US-6313153-B1 | ADMINISTERING PYRIDYLACRYLAMIDE COMPOUND FOR THERAPY OF NEPHRITIS | TSUMURA & CO. (JP) | 2001-11-06 | — | — | US | disclosed |
| US-6291530-B1 | Aryl-substituted acrylamides with Leukotriene B4 (LTB-4) receptor antagonist activity | NOVARTIS AG (CH) | 2001-09-18 | — | — | US | disclosed |
| EP-1000935-A1 | PYRIDYLACRYLAMIDE DERIVATIVES AND NEPHRITIS REMEDIES AND TGF-$g(b) INHIBITORS CONTAINING THE SAME | TSUMURA & CO. (JP) | 2000-05-17 | — | — | EP | disclosed |
| EP-1000935-A1 | PYRIDYLACRYLAMIDE DERIVATIVES AND NEPHRITIS REMEDIES AND TGF-$g(b) INHIBITORS CONTAINING THE SAME | TSUMURA & CO. (JP) | 2000-05-17 | — | — | EP | disclosed |
| EP-0942903-A1 | ARYL-SUBSTITUTED ACRYLAMIDES WITH LEUKOTRIENE B4 (LTB-4) RECEPTOR ANTAGONIST ACTIVITY | Novartis AG (CH) | 1999-09-22 | — | — | EP | disclosed |
| WO-1998013347-A1 | ARYL-SUBSTITUTED ACRYLAMIDES WITH LEUKOTRIENE B4 (LTB-4) RECEPTOR ANTAGONIST ACTIVITY | NOVARTIS AG (CH) | 1998-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187264-A1 | Phosphodiesterase iv inhibitor containing pyridylacrylamide derivative | PDE3B, PDE3A, PDE2A | CES2 1281/4885CES1 618/4885LMNA 3646/4885 |
| US-20230312646-A1 | ANTIBACTERIAL PEPTIDES | VIP, NRDC, CLPP | CES2 4831/4885CES1 4778/4885LMNA 4169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.